Biosimilar Insulin Market Access
Biosimilar Insulin Market Access
$2,995.00
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba. More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers’ formularies and contracts.
- Description
- Contents
- Samples
Overview
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba. More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers’ formularies and contracts.
Table of Contents
4 EXECUTIVE SUMMARY
5 US
5 Insights and strategic recommendations
5 US payers are adopting a wait-and-see approach for biosimilar Basaglar
7 Bibliography
8 FIVE MAJOR EU MARKETS
8 Insights and strategic recommendations
8 Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
8 Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to
reduce costs
10 Payers use biosimilars to pressure originators on pricing
11 Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
12 Patient switching requires significant discounts of at least 30%
13 Given attractive discounts, payers will use a variety of market access tools to drive Basaglar’s uptake
17 Bibliography
18 METHODOLOGY
18 Primary research
LIST OF TABLES
15 Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Crenezumab